Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549183 | 0.90 | LMNA (0.33) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL19206510 | 0.82 | PDE3A (0.34) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL19206595 | 0.81 | PDE3A (0.39) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL19206358 | 0.80 | CACNA1F (0.31) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL17725082 | 0.80 | CACNA1F (0.31) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL23610433 | 0.76 | LMNA (0.32) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL23620976 | 0.73 | STING1 (0.37) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL23620978 | 0.73 | STING1 (0.37) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL23620958 | 0.73 | STING1 (0.37) | CACNA1FLMNAALBMAPTCACNA1D | |
| SCHEMBL26019436 | 0.73 | STING1 (0.37) | CACNA1FLMNAALBMAPTCACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214090-B1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2020-08-19 | — | — | EP | claimed |
| EP-3214090-B1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, KRAS | CACNA1F 4440/4885LMNA 4093/4885ALB 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.